Since the platinum–etoposide combination regimen remains the first-line treatment option for SCLC, CDDP and VP16 were simultaneously used to study whether METTL3 is involved in SCLC chemoresistance in vivo. This evidence concerns the gene METTL3 and small cell lung carcinoma.